Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 60 entries
Sorted by: Best Match Show Resources per page
Electronic Degeneracy and Intrinsic Magnetic Properties of EpitaxialNb: SrTiO3 Thin Films Controlled by Defects.

Physical review letters

Sarantopoulos A, Ferreiro-Vila E, Pardo V, Magén C, Aguirre MH, Rivadulla F.
PMID: 26550891
Phys Rev Lett. 2015 Oct 16;115(16):166801. doi: 10.1103/PhysRevLett.115.166801. Epub 2015 Oct 14.

We report thermoelectric power experiments in e-doped thin films of SrTiO3 (STO) which demonstrate that the electronic band degeneracy can be lifted through defect management during growth. We show that even small amounts of cationic vacancies, combined with epitaxial...

Cite
Sarantopoulos A, Ferreiro-Vila E, Pardo V, et al. Electronic Degeneracy and Intrinsic Magnetic Properties of EpitaxialNb: SrTiO3 Thin Films Controlled by Defects. Phys Rev Lett. 2015;115(16):166801doi: 10.1103/PhysRevLett.115.166801.
Sarantopoulos, A., Ferreiro-Vila, E., Pardo, V., Magén, C., Aguirre, M. H., & Rivadulla, F. (2015). Electronic Degeneracy and Intrinsic Magnetic Properties of EpitaxialNb: SrTiO3 Thin Films Controlled by Defects. Physical review letters, 115(16), 166801. https://doi.org/10.1103/PhysRevLett.115.166801
Sarantopoulos, A, et al. "Electronic Degeneracy and Intrinsic Magnetic Properties of EpitaxialNb: SrTiO3 Thin Films Controlled by Defects." Physical review letters vol. 115,16 (2015): 166801. doi: https://doi.org/10.1103/PhysRevLett.115.166801
Sarantopoulos A, Ferreiro-Vila E, Pardo V, Magén C, Aguirre MH, Rivadulla F. Electronic Degeneracy and Intrinsic Magnetic Properties of EpitaxialNb: SrTiO3 Thin Films Controlled by Defects. Phys Rev Lett. 2015 Oct 16;115(16):166801. doi: 10.1103/PhysRevLett.115.166801. Epub 2015 Oct 14. PMID: 26550891.
Copy Download .nbib Format: NLM
What can photophobia tell us about dry eye?.

Expert review of ophthalmology

Galor A, Levitt RC, Felix ER, Sarantopoulos CD.
PMID: 28845186
Expert Rev Ophthalmol. 2016;11(5):321-324. doi: 10.1080/17469899.2016.1222905. Epub 2016 Aug 23.

No abstract available.

Cite
Galor A, Levitt RC, Felix ER, et al. What can photophobia tell us about dry eye?. Expert Rev Ophthalmol. 2016;11(5):321-324doi: 10.1080/17469899.2016.1222905.
Galor, A., Levitt, R. C., Felix, E. R., & Sarantopoulos, C. D. (2016). What can photophobia tell us about dry eye?. Expert review of ophthalmology, 11(5), 321-324. https://doi.org/10.1080/17469899.2016.1222905
Galor, Anat, et al. "What can photophobia tell us about dry eye?." Expert review of ophthalmology vol. 11,5 (2016): 321-324. doi: https://doi.org/10.1080/17469899.2016.1222905
Galor A, Levitt RC, Felix ER, Sarantopoulos CD. What can photophobia tell us about dry eye?. Expert Rev Ophthalmol. 2016;11(5):321-324. doi: 10.1080/17469899.2016.1222905. Epub 2016 Aug 23. PMID: 28845186; PMCID: PMC5571866.
Copy Download .nbib Format: NLM
Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center.

Hippokratia

Boura P, Tselios K, Skendros P, Kamali S, Sarantopoulos A, Raptopoulou-Gigi M.
PMID: 19582197
Hippokratia. 2007 Oct;11(4):210-5.

UNLABELLED: OBJECTIVE-METHODS: Adamantiades-Behcet disease (ABD) is a multi-systemic vasculitis of unknown origin, with a characteristic geographic distribution, that affects vessels of all kinds and sizes and is characterized by recurrent mucosal, skin and ocular lesions. In the present study,...

Cite
Boura P, Tselios K, Skendros P, et al. Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center. Hippokratia. 2007;11(4):210-5
Boura, P., Tselios, K., Skendros, P., Kamali, S., Sarantopoulos, A., & Raptopoulou-Gigi, M. (2007). Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center. Hippokratia, 11(4), 210-5.
Boura, P, et al. "Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center." Hippokratia vol. 11,4 (2007): 210-5.
Boura P, Tselios K, Skendros P, Kamali S, Sarantopoulos A, Raptopoulou-Gigi M. Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center. Hippokratia. 2007 Oct;11(4):210-5. PMID: 19582197; PMCID: PMC2552987.
Copy Download .nbib Format: NLM
beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA.
PMID: 17335133
J BUON. 2005 Jan-Mar;10(1):59-69.

PURPOSE: Serum beta-2 microglobulin (sbeta(2)m) is an established prognostic factor for several lymphoproliferative disorders. Because its significance in Hodgkin's lymphoma (HL) is controversial, we determined sbeta(2)m levels in pretreatment serum samples of patients with HL in order to elucidate...

Cite
Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. J BUON. 2005;10(1):59-69
Vassilakopoulos, T. P., Nadali, G., Angelopoulou, M. K., Dimopoulou, M. N., Siakantaris, M. P., Kontopidou, F. N., Karkantaris, C., Kokoris, S. I., Dimitriadou, E. M., Calpadaki, C., Sarantopoulos, A., Galani, Z., Sachanas, S., Kyrtsonis, M. C., Tsaftaridis, P., Variamis, E., Panayotidis, P., Pizzolo, G., Sarris, A. H., & Pangalis, G. A. (2005). beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 10(1), 59-69.
Vassilakopoulos, T P, et al. "beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens." Journal of B.U.ON. : official journal of the Balkan Union of Oncology vol. 10,1 (2005): 59-69.
Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA. beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. J BUON. 2005 Jan-Mar;10(1):59-69. PMID: 17335133.
Copy Download .nbib Format: NLM
Formation of core-shell and hollow nanospheres through the nanoscale melt-solidification effect in the Sm-Fe(Ta)-N system.

Nanotechnology

Sturm S, Rožman KZ, Markoli B, Sarantopoulou E, Kollia Z, Cefalas AC, Kobe S.
PMID: 21063053
Nanotechnology. 2010 Dec 03;21(48):485603. doi: 10.1088/0957-4484/21/48/485603. Epub 2010 Nov 10.

Sm-Fe-Ta-N-O nanospheres were synthesized by pulsed-laser deposition from a Sm(13.8)Fe(82.2)Ta(4.0) target in a nitrogen atmosphere. Three structurally and compositionally distinct types were identified: amorphous, core-shell and hollow nanospheres. Amorphous spheres were compositionally homogeneous and completely oxidized. The core-shell spheres...

Cite
Sturm S, Rožman KZ, Markoli B, et al. Formation of core-shell and hollow nanospheres through the nanoscale melt-solidification effect in the Sm-Fe(Ta)-N system. Nanotechnology. 2010;21(48):485603doi: 10.1088/0957-4484/21/48/485603.
Sturm, S., Rožman, K. Z., Markoli, B., Sarantopoulou, E., Kollia, Z., Cefalas, A. C., & Kobe, S. (2010). Formation of core-shell and hollow nanospheres through the nanoscale melt-solidification effect in the Sm-Fe(Ta)-N system. Nanotechnology, 21(48), 485603. https://doi.org/10.1088/0957-4484/21/48/485603
Sturm, S, et al. "Formation of core-shell and hollow nanospheres through the nanoscale melt-solidification effect in the Sm-Fe(Ta)-N system." Nanotechnology vol. 21,48 (2010): 485603. doi: https://doi.org/10.1088/0957-4484/21/48/485603
Sturm S, Rožman KZ, Markoli B, Sarantopoulou E, Kollia Z, Cefalas AC, Kobe S. Formation of core-shell and hollow nanospheres through the nanoscale melt-solidification effect in the Sm-Fe(Ta)-N system. Nanotechnology. 2010 Dec 03;21(48):485603. doi: 10.1088/0957-4484/21/48/485603. Epub 2010 Nov 10. PMID: 21063053.
Copy Download .nbib Format: NLM
A Case of Atypical Lymphocytic Lobular Panniculitis.

Cureus

Ni CS, Sarantopoulos GP, Chiu M.
PMID: 32257679
Cureus. 2020 Feb 28;12(2):e7134. doi: 10.7759/cureus.7134.

Atypical lymphocytic lobular panniculitis (ALLP) is a rare T-cell dyscrasia of the subcutaneous fat. It typically presents with indurated erythematous nodules on the lower extremities and often will have a relapsing and remitting course. The cause is unknown, but...

Cite
Ni CS, Sarantopoulos GP, Chiu M. A Case of Atypical Lymphocytic Lobular Panniculitis. Cureus. 2020;12(2):e7134doi: 10.7759/cureus.7134.
Ni, C. S., Sarantopoulos, G. P., & Chiu, M. (2020). A Case of Atypical Lymphocytic Lobular Panniculitis. Cureus, 12(2), e7134. https://doi.org/10.7759/cureus.7134
Ni, Catherine S, et al. "A Case of Atypical Lymphocytic Lobular Panniculitis." Cureus vol. 12,2 (2020): e7134. doi: https://doi.org/10.7759/cureus.7134
Ni CS, Sarantopoulos GP, Chiu M. A Case of Atypical Lymphocytic Lobular Panniculitis. Cureus. 2020 Feb 28;12(2):e7134. doi: 10.7759/cureus.7134. PMID: 32257679; PMCID: PMC7105265.
Copy Download .nbib Format: NLM
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.

Cancers

Mahalingam D, Peguero J, Cen P, Arora SP, Sarantopoulos J, Rowe J, Allgood V, Tubb B, Campos L.
PMID: 31212948
Cancers (Basel). 2019 Jun 17;11(6). doi: 10.3390/cancers11060833.

No abstract available.

Cite
Mahalingam D, Peguero J, Cen P, et al. A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. Cancers (Basel). 2019;11(6)doi: 10.3390/cancers11060833.
Mahalingam, D., Peguero, J., Cen, P., Arora, S. P., Sarantopoulos, J., Rowe, J., Allgood, V., Tubb, B., & Campos, L. (2019). A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. Cancers, 11(6), . https://doi.org/10.3390/cancers11060833
Mahalingam, Devalingam, et al. "A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma." Cancers vol. 11,6 (2019). doi: https://doi.org/10.3390/cancers11060833
Mahalingam D, Peguero J, Cen P, Arora SP, Sarantopoulos J, Rowe J, Allgood V, Tubb B, Campos L. A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. Cancers (Basel). 2019 Jun 17;11(6). doi: 10.3390/cancers11060833. PMID: 31212948; PMCID: PMC6627768.
Copy Download .nbib Format: NLM
First Report of .

Pathogens (Basel, Switzerland)

Komnenou AT, Gkafas GA, Kofidou E, Sarantopoulou J, Exadactylos A, Tounta E, Koemtzopoulos K, Dendrinos P, Karamanlidis AA, Gulland F, Papadopoulos E.
PMID: 34959536
Pathogens. 2021 Dec 03;10(12). doi: 10.3390/pathogens10121581.

The Mediterranean monk seal (

Cite
Komnenou AT, Gkafas GA, Kofidou E, et al. First Report of . Pathogens. 2021;10(12)doi: 10.3390/pathogens10121581.
Komnenou, A. T., Gkafas, G. A., Kofidou, E., Sarantopoulou, J., Exadactylos, A., Tounta, E., Koemtzopoulos, K., Dendrinos, P., Karamanlidis, A. A., Gulland, F., & Papadopoulos, E. (2021). First Report of . Pathogens (Basel, Switzerland), 10(12), . https://doi.org/10.3390/pathogens10121581
Komnenou, Anastasia Th, et al. "First Report of ." Pathogens (Basel, Switzerland) vol. 10,12 (2021). doi: https://doi.org/10.3390/pathogens10121581
Komnenou AT, Gkafas GA, Kofidou E, Sarantopoulou J, Exadactylos A, Tounta E, Koemtzopoulos K, Dendrinos P, Karamanlidis AA, Gulland F, Papadopoulos E. First Report of . Pathogens. 2021 Dec 03;10(12). doi: 10.3390/pathogens10121581. PMID: 34959536; PMCID: PMC8708642.
Copy Download .nbib Format: NLM
Photons Probe Entropic Potential Variation during Molecular Confinement in Nanocavities.

Entropy (Basel, Switzerland)

Gavriil V, Chatzichristidi M, Kollia Z, Cefalas AC, Spyropoulos-Antonakakis N, Semashko VV, Sarantopoulou E.
PMID: 33265634
Entropy (Basel). 2018 Jul 24;20(8). doi: 10.3390/e20080545.

In thin polymeric layers, external molecular analytes may well be confined within tiny surface nano/microcavities, or they may be attached to ligand adhesion binding sites via electrical dipole forces. Even though molecular trapping is followed by a variation of...

Cite
Gavriil V, Chatzichristidi M, Kollia Z, et al. Photons Probe Entropic Potential Variation during Molecular Confinement in Nanocavities. Entropy (Basel). 2018;20(8)doi: 10.3390/e20080545.
Gavriil, V., Chatzichristidi, M., Kollia, Z., Cefalas, A. C., Spyropoulos-Antonakakis, N., Semashko, V. V., & Sarantopoulou, E. (2018). Photons Probe Entropic Potential Variation during Molecular Confinement in Nanocavities. Entropy (Basel, Switzerland), 20(8), . https://doi.org/10.3390/e20080545
Gavriil, Vassilios, et al. "Photons Probe Entropic Potential Variation during Molecular Confinement in Nanocavities." Entropy (Basel, Switzerland) vol. 20,8 (2018). doi: https://doi.org/10.3390/e20080545
Gavriil V, Chatzichristidi M, Kollia Z, Cefalas AC, Spyropoulos-Antonakakis N, Semashko VV, Sarantopoulou E. Photons Probe Entropic Potential Variation during Molecular Confinement in Nanocavities. Entropy (Basel). 2018 Jul 24;20(8). doi: 10.3390/e20080545. PMID: 33265634; PMCID: PMC7513070.
Copy Download .nbib Format: NLM
An Unusual Case of Malignant Struma Ovarii Causing Thyrotoxicosis.

European thyroid journal

Anagnostou E, Polymeris A, Morphopoulos G, Travlos A, Sarantopoulou V, Papaspyrou I.
PMID: 27843812
Eur Thyroid J. 2016 Sep;5(3):207-211. doi: 10.1159/000448474. Epub 2016 Sep 08.

BACKGROUND: Struma ovarii (SO) is a specialized monodermal teratoma predominantly composed of mature thyroid tissue, accounting for approximately 5% of all ovarian teratomas. Thyrotoxicosis is seen in about 8% of patients with SO. Most SO cases are benign with...

Cite
Anagnostou E, Polymeris A, Morphopoulos G, et al. An Unusual Case of Malignant Struma Ovarii Causing Thyrotoxicosis. Eur Thyroid J. 2016;5(3):207-211doi: 10.1159/000448474.
Anagnostou, E., Polymeris, A., Morphopoulos, G., Travlos, A., Sarantopoulou, V., & Papaspyrou, I. (2016). An Unusual Case of Malignant Struma Ovarii Causing Thyrotoxicosis. European thyroid journal, 5(3), 207-211. https://doi.org/10.1159/000448474
Anagnostou, Elli, et al. "An Unusual Case of Malignant Struma Ovarii Causing Thyrotoxicosis." European thyroid journal vol. 5,3 (2016): 207-211. doi: https://doi.org/10.1159/000448474
Anagnostou E, Polymeris A, Morphopoulos G, Travlos A, Sarantopoulou V, Papaspyrou I. An Unusual Case of Malignant Struma Ovarii Causing Thyrotoxicosis. Eur Thyroid J. 2016 Sep;5(3):207-211. doi: 10.1159/000448474. Epub 2016 Sep 08. PMID: 27843812; PMCID: PMC5091280.
Copy Download .nbib Format: NLM
TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells.

Frontiers in immunology

Suthers AN, Sarantopoulos S.
PMID: 28751890
Front Immunol. 2017 Jul 13;8:775. doi: 10.3389/fimmu.2017.00775. eCollection 2017.

B cells are capable of receptor-mediated responses to foreign antigens. Recognition of microbial-derived nucleic acid (NA) by toll-like receptors (TLRs) 7 and 9 in B cells has been substantiated. Endogenous NA released from damaged or dying cells can also...

Cite
Suthers AN, Sarantopoulos S. TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells. Front Immunol. 2017;8:775doi: 10.3389/fimmu.2017.00775.
Suthers, A. N., & Sarantopoulos, S. (2017). TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells. Frontiers in immunology, 8775. https://doi.org/10.3389/fimmu.2017.00775
Suthers, Amy N, and Sarantopoulos, Stefanie. "TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells." Frontiers in immunology vol. 8 (2017): 775. doi: https://doi.org/10.3389/fimmu.2017.00775
Suthers AN, Sarantopoulos S. TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells. Front Immunol. 2017 Jul 13;8:775. doi: 10.3389/fimmu.2017.00775. eCollection 2017. PMID: 28751890; PMCID: PMC5507964.
Copy Download .nbib Format: NLM
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.

Experimental hematology & oncology

Brown J, Plummer R, Bauer TM, Anthony S, Sarantopoulos J, De Vos F, White M, Schupp M, Ou Y, Vaishampayan U.
PMID: 29026685
Exp Hematol Oncol. 2017 Oct 03;6:27. doi: 10.1186/s40164-017-0086-1. eCollection 2017.

BACKGROUND: Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with relapsed or progressive advanced malignancies and varying degrees...

Cite
Brown J, Plummer R, Bauer TM, et al. Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Exp Hematol Oncol. 2017;6:27doi: 10.1186/s40164-017-0086-1.
Brown, J., Plummer, R., Bauer, T. M., Anthony, S., Sarantopoulos, J., De Vos, F., White, M., Schupp, M., Ou, Y., & Vaishampayan, U. (2017). Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Experimental hematology & oncology, 627. https://doi.org/10.1186/s40164-017-0086-1
Brown, Jennifer, et al. "Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study." Experimental hematology & oncology vol. 6 (2017): 27. doi: https://doi.org/10.1186/s40164-017-0086-1
Brown J, Plummer R, Bauer TM, Anthony S, Sarantopoulos J, De Vos F, White M, Schupp M, Ou Y, Vaishampayan U. Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Exp Hematol Oncol. 2017 Oct 03;6:27. doi: 10.1186/s40164-017-0086-1. eCollection 2017. PMID: 29026685; PMCID: PMC5627448.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 60 entries